The University of Oxford has produced Coronavirus vaccine for adults aged 56-69 and those over 70.
Developed by teams in the university, ChAdOx1 nCov-2019 Coronavirus vaccine reportedly triggers a robust immune response in healthy adults.
The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.
Older adults are prone to higher risk from COVID-19 and immunization is more effective vaccine for the disease.
At Phase II trial of the ChAdOx1 nCov-2019 vaccine, the authors agreed that volunteers in the trial demonstrate similar neutralising antibody titres, and T cell responses across all three age groups (18-55, 56-79, and 70+).
During the Phase 2 trial, the vaccine was evaluated in 560 healthy adult volunteers of ages 18-55, 56-69 and 70 or above.
Volunteers received two doses of the vaccine ChAdOx1 nCoV-19, or a placebo MenACWY vaccine. No serious adverse health events related to ChAdOx1 nCoV-19 were seen in the volunteers.
These data are consistent with the Phase I data reported for healthy adults aged 18-55 early this year.
Dr Maheshi Ramasamy, Investigator at the Oxford Vaccine Group and Consultant Physician said: “Older adults are a priority group for COVID-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses.
“We were pleased to see that our vaccine was not only well tolerated in older adults; it also stimulated similar immune responses to those seen in younger volunteers. The next step will be to see if this translates into protection from the disease itself.”
For most vaccines, older adults do not exhibit as strong a response as younger adults, and vaccine-induced antibodies commonly display a lower protective capacity.
Dr Angela Minassian, Investigator at the University of Oxford and Honorary Consultant in Infectious Diseases, said, “Inducing robust immune responses in older adults has been a long-standing challenge in human vaccine research.’
“To show this vaccine technology is able to induce these responses, in the age group most at risk from severe COVID-19 disease, offers hope that vaccine efficacy will be similar in younger and older adults.”
In addition, the vaccine is likely to cause local reactions at the injection site and symptoms on the day of vaccination in older adults than in the younger group, demonstrating that assessment of the efficacy of the vaccine is warranted in all age groups.
The Phase III trials of the ChAdOx1 nCov-2019 vaccine are ongoing, with early efficacy readings possible in the coming weeks.
